A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness

Journal of Psychiatric Practice

Volumn 13, Issue 2, 2007, Pages 129-137

  Megna, James L ^a,e   Kunwar, Arun R ^a   Mahlotra, Kamna ^b   Sauro, Marie D ^c   Devitt, Patrick J ^d   Rashid, Ayesha ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b LEHIGH VALLEY HOSPITAL   (United States)

^c UNIVERSITY OF MASSACHUSETTS DARTMOUTH   (United States)

^d ADELAIDE AND MEATH HOSPITAL   (Ireland)

^e State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Atypical antipsychotic; Polypharmacy; Schizoaffective disorder; Schizophrenia; Second generation antipsychotic; Serious and persistent mental illness

Indexed keywords

AMANTADINE; BENZATROPINE; CLONAZEPAM; CLOZAPINE; ETHINYLESTRADIOL PLUS NORGESTREL; FLUOXETINE; FLUPHENAZINE; GABAPENTIN; GLIBENCLAMIDE; HALOPERIDOL; HALOPERIDOL DECANOATE; IBUPROFEN; LEVOTHYROXINE; LORAZEPAM; MEVINOLIN; NEFAZODONE; OLANZAPINE; PAROXETINE; PERPHENAZINE; PHENYTOIN; QUETIAPINE; RISPERIDONE; SERTRALINE; SIMVASTATIN; TAMOXIFEN; VALPROIC ACID;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITALIZATION; HUMAN; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; POLYPHARMACY; PRESCRIPTION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CHOLINERGIC ANTAGONISTS; CLOZAPINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 34247122282     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000265773.03756.3e     Document Type: Article

References (38)

1. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, 2nd edition. Am J Psychiatry 2004;161(2 Suppl):1-56.
2. Gmurkowski K, Szafranski T. Clozapine treatment: Possibilities and limitations. Psychiatr Pol 1999;33:37-50.
3. Stahl SM. Antipsychotic polypharmacy: Squandering precious resources? J Clin Psychiatry 2002;63:93-4.
4. Honer WG, Thornton AE, Chen ETH, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;354:477-82.
5. Yagcioglu AEA, Akdede BBK, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: Efficacy and safety. J Clin Psychiatry 2005;66:63-72.
6. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Res 1988;23:99-110.
7. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: A randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005;162:130-6.
8. Davis JM. The choice of drugs for schizophrenia. N Engl J Med 2006; 354:518-20.
9. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled study. Br J Psychiatry 1997;171:569-73.
10. Overall, JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Report 1962;10:799-812.
11. Potter WZ, Ko GN, Zhang LD, et al. Clozapine in China: A review and preview of US/PRC collaboration. Psychopharmacology (Berl) 1989;99:587-97.
12. Nishikawa T, Tsuda A, Tanaka M, et al. Prophylactic effects of neuroleptics in symptom-free schizophrenics: Roles of dopaminergic and noradrenergic blockers. Biol Psychiatry 1985;20:1161-6.
13. Knight RG, Harrison A. A double-blind comparison of thiothixene and a trifluoperazine/chlorpromazine composite in the treatment of schizophrenia. NZ Med J 1979;89:302-4.
14. Taylor CG, Flynn SW, Altman S, et al. An open trial of risperidone augmentation of partial response to clozapine. Schizophr Res 2001;48:155-8.
15. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996;57:395-7.
16. de Groot IW, Heck AH, Van Harten PN. Addition of risperidone to clozapine therapy in chronically psychotic inpatients. J Clin Psychiatry 2001;62:129-30.
17. Friedman J, Ault K, Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol Psychiatry 1997;42:522-3.
18. Guyatt GH, Sacket DL, Cook DJ. Users' guide to the medical literature. JAMA 1993;270:2598-601.
19. Patrick VK, Levin E, Schleifer S. Antipsychotic polypharmacy: Is there evidence for its use? J Psychiatr Pract 2005;11:248-57.
20. Chan J, Sweeting M. Combination therapy with non-clozapine atypical antipsychotic medication: A review of current evidence. J Psychopharm 2006; Nov 8 [Epub ahead of print]
21. Preskorn SH, Lacey RL. Polypharmacy: When is it rational? Journal of Practical Psychiatry and Behavioral Health 1995;1:92-8: Reprinted J Psychiatr Pract 2007;13:97-105.
22. Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits. Am J Psychiatry 2004;161:700-6.
23. McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatry 2003;64:984-9.
24. Schinnar AP, Rothbond AB, Kanter R, et al. An empirical literature review of "definitions" of severe and persistent mental illness. Am J Psychiatry 1990;147:1602-8.
25. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004;24:192-208.
26. Guy W. ECDEU assessment manual for psychopharmacology-revised (DHEW Publ. No ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs 1976:218-22.
27. Guy W. ECDEU assessment manual for psychopharmacology-revised (DHEW Publ. No ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs 1976: 534-7.
28. Megna JL, Devitt PJ, Sauro MD, et al. Gabapentin's effect on agitation in severely and persistently mentally ill patients. Ann Pharmacotherapy 2002;36:12-6.
29. Lehman AF, Steinwachs DM. Patterns of usual care for schizophrenia: Initial results from the Schizophrenia Patient Outcomes Research Team (PORT) client survey. Schizophr Bull 1998;24:11-20; discussion 20-32.
30. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003. Schizophr Bull 2004;30:193-217.
31. Rosenheck R, Tekell J, Peters J, et al. Does participation in psychosocial treatment augment the benefit of clozapine? Department of Veteran Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Arch Gen Psychiatry 1998;55:618-25.
32. McIntryre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: Weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001;46:273-81.
33. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004;27:596-601.
34. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-49.
35. Biological therapies. In: Sadock BJ, Sadock VA, eds. Synopsis of psychiatry. 9th edition. Philadelphia: Lippincott, Williams & Wilkins 2003:1104-13.
36. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia: A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002;106:323-30.
37. Tyson SC, Devan CL, Risch SC. Pharmacokinetic interaction between risperidone and clozapine. Am J Psychiatry 1995;152:1401-2.
38. Waddington JL, Youssef HA, Kinsella A. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998;173:325-9.